Current Operational Subsidiaries
Delex Pharma International Inc.
Delex Pharma International, Inc. (DPI), a socially accountable Filipino-owned and ISO 9001:2015-certified company, has continuously served its nationwide market for fourteen years. The company is 60% owned by DLX Holdings, Inc. and 40% owned by High Everest Capital Inc.
The profound ideas of venturing into the pharmaceutical industry from its competent award-winning leaders commenced on July 13, 2009. They continued to expand, establishing more businesses in medical devices and retail pharmacy (with three branches).
DPI offers cost-effective and quality ICU drugs and medical devices manufactured by GMP-certified multinational companies (list and copy of agreements included in the index). It distributes and promotes various products in the critical care, anesthesia, medical devices, and oncology fields, housed in its government-compliant warehouses with a total lot area of 1,224 square meters.
Meanwhile, as the company strives for excellence in meeting the gaps in critical care, it has gained the trust of its clients in the hospital channels, drug chains, and diagnostic laboratories.
Furthermore, DPI continues to nurture its almost two hundred (200) employees.
DLX Holdings Corp.
DLX Holdings Corp., (DLX) the subsidiary of our company, was registered in December 2012, and is the parent company of Delex Pharma International Inc. (DPI). DLX is engaged in the development, distribution and trading of medical supplies, equipment, pharmaceutical products, and food supplements.
JMN Brothers Pharma Limited Inc.
JMN Brothers Pharma Limited, Inc., a subsidiary company of Delex Pharma, was founded in the Philippines on June 27, 2016, by the management heading the latter organization. Although it is a new player in the market, it has slowly made rounds to become one of the trusted companies in the country, focusing on women’s health and ethical products.